What We Know From Injectable Tirzepatide From FDA-approved use, known side effects include: Nausea, vomiting, diarrhea Appetite suppression Fatigue Gallbladder complications Rare but serious risks such as pancreatitis These risks are dose-dependent and monitored in clinical settings
Here's what to expect: Typical Semaglutide Titration: Weeks 1-4: 0.25 mg weekly (lowest dose) Weeks 5-8: 0.5 mg weekly Weeks 9-12: 1.0 mg weekly Weeks 13-16: 1.7 mg weekly Week 17+: 2.4 mg weekly (maintenance) Typical Tirzepatide Titration: Weeks 1-4: 2.5 mg weekly Weeks 5-8: 5 mg weekly Weeks 9-12: 7.5 mg weekly Weeks 13-16: 10 mg weekly Weeks 17-20: 12.5 mg weekly Week 21+: 15 mg weekly (maintenance) You'll have a nurse check-in at each dose adjustment to monitor tolerability, appetite suppression, weight change, and side effects
Importantly, the QMP substitutions did not affect the ability of GLP-1 to activate the GLP-1R
This is a concierge, physician-led program personalized care directly with Dr
How should I contact your office with questions or if Im worried about something